The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage

Abstract Background Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) represents a novel therapeutic approach for renal anemia, a prevalent complication of chronic kidney disease (CKD). However, the effects of HIF-PHI on renal functional outcomes remain poorly characterized. Here, the...

Full description

Bibliographic Details
Published in:Cell Communication and Signaling
Main Authors: Jing Wang, Zuo-Lin Li, Yan Zhou, Zhong-Tang Li, Yan Tu, Xin-Hui Hu, Jin-Hua Zhu, Bi-Cheng Liu, Hong Liu
Format: Article
Language:English
Published: BMC 2025-04-01
Subjects:
Roxadustat
Tubulointerstitial fibrosis
FGF23
Anemia
Furin
Online Access:https://doi.org/10.1186/s12964-025-02175-2

Internet

https://doi.org/10.1186/s12964-025-02175-2

Similar Items